Share this article
Share this article
ROCHESTER, N.Y., Jan. 7, 2021 /PRNewswire/ OyaGen, Inc. announced today publication in VIRUSES, a peer reviewed journal, of studies carried out by OyaGen in collaboration with NIH/NIAID Integrated Research Facility at Fort Detrick MD. This Study identified OYA1 as a highly effective antiviral against several viruses including Ebola and Lassa viruses.
Bennett et al., A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures. (2021)
About OYA1. OYA1 (a.k.a. sangivamycin) has broad-spectrum antiviral activity in laboratory-based assays against several viruses. The published study results showed that OYA1 was highly effective in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID. The data also suggest that OYA1 could be significantly more potent than Gilead Science s remdesivir. In vitro studies showed that when OY